Nifty
Sensex
:
:
20267.90
67481.19
134.75 (0.67%)
492.75 (0.74%)

Pharmaceuticals & Drugs - Global

Rating :
52/99

BSE: 532531 | NSE: STAR

502.35
01-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  489.00
  •  505.90
  •  489.00
  •  486.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  833660
  •  4170.79
  •  549.00
  •  268.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,618.64
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,028.63
  • 0.30%
  • 2.18

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 27.78%
  • 7.45%
  • 23.39%
  • FII
  • DII
  • Others
  • 17.21%
  • 18.66%
  • 5.51%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.65
  • 3.48
  • 3.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.60
  • 5.37
  • -9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -48.42
  • -46.85
  • -60.89

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.12
  • 5.01
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.20
  • 1.72
  • 1.81

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.12
  • 15.93
  • 18.67

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
999.43
897.10
11.41%
929.99
940.07
-1.07%
986.37
866.02
13.90%
864.85
794.39
8.87%
Expenses
846.30
798.97
5.92%
763.40
879.92
-13.24%
830.81
823.85
0.84%
748.50
792.86
-5.59%
EBITDA
153.13
98.13
56.05%
166.59
60.15
176.96%
155.56
42.16
268.98%
116.34
1.53
7,503.92%
EBIDTM
15.32%
10.94%
17.91%
6.40%
15.77%
4.87%
13.45%
0.19%
Other Income
35.85
23.46
52.81%
8.64
13.55
-36.24%
27.12
86.06
-68.49%
26.20
10.19
157.11%
Interest
78.59
67.64
16.19%
76.42
54.54
40.12%
80.52
49.48
62.73%
58.44
42.25
38.32%
Depreciation
60.10
61.70
-2.59%
59.59
60.40
-1.34%
60.93
60.68
0.41%
60.22
60.90
-1.12%
PBT
-114.64
6.77
-
33.25
-107.01
-
33.89
-58.88
-
65.44
-106.86
-
Tax
-7.44
-38.40
-
9.68
-28.07
-
7.09
-131.48
-
4.09
-4.48
-
PAT
-107.20
45.17
-
23.57
-78.94
-
26.81
72.60
-63.07%
61.35
-102.38
-
PATM
-10.73%
5.04%
2.53%
-8.40%
2.72%
8.38%
7.09%
-12.89%
EPS
-14.54
2.53
-
-0.79
-15.13
-
-1.06
3.25
-
-8.86
-13.55
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
3,780.64
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
Net Sales Growth
8.09%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
 
Cost Of Goods Sold
1,571.24
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
Gross Profit
2,209.40
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
GP Margin
58.44%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
Total Expenditure
3,189.01
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
Power & Fuel Cost
-
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
18.56
% Of Sales
-
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
Employee Cost
-
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
157.18
% Of Sales
-
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
Manufacturing Exp.
-
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
35.76
% Of Sales
-
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
General & Admin Exp.
-
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
66.37
% Of Sales
-
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
Selling & Distn. Exp.
-
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
66.67
% Of Sales
-
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
Miscellaneous Exp.
-
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
29.44
66.67
% Of Sales
-
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
EBITDA
591.62
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
223.42
EBITDA Margin
15.65%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
Other Income
97.81
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
60.23
Interest
293.97
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
108.88
Depreciation
240.84
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
56.48
PBT
17.94
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
118.30
Tax
13.42
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
40.86
Tax Rate
74.80%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
PAT
4.53
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
50.89
PAT before Minority Interest
31.22
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
50.89
Minority Interest
26.69
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
PAT Margin
0.12%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
PAT Growth
107.13%
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
 
EPS
0.50
-24.50
-50.96
39.02
15.90
41.01
75.45
44.23
12.54
0.17
5.64

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
Share Capital
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
59.57
Total Reserves
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
Non-Current Liabilities
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
Secured Loans
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
Unsecured Loans
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
1.24
Long Term Provisions
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
16.56
Current Liabilities
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
Trade Payables
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
262.31
Other Current Liabilities
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
127.27
Short Term Borrowings
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
Short Term Provisions
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
93.23
Total Liabilities
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
Net Block
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
Gross Block
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
Accumulated Depreciation
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
352.80
Non Current Assets
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
Capital Work in Progress
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
99.47
Non Current Investment
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
41.80
Long Term Loans & Adv.
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
90.40
Other Non Current Assets
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
1.45
Current Assets
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
Current Investments
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
Inventories
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
175.99
Sundry Debtors
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
Cash & Bank
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
231.15
Other Current Assets
322.55
647.90
98.22
83.57
385.98
434.59
454.09
343.44
123.64
136.26
Short Term Loans & Adv.
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
79.06
Net Current Assets
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
Total Assets
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
PBT
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
Adjustment
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
Changes in Working Capital
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
Cash after chg. in Working capital
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
Net Fixed Assets
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
Net Investments
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
Others
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
Cash from Financing Activity
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
Net Cash Inflow / Outflow
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
Opening Cash & Equivalents
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
Closing Cash & Equivalent
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
168.99
ROA
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
ROE
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
ROCE
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
Fixed Asset Turnover
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
0.61
Receivable days
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
114.80
Inventory Days
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
83.78
Payable days
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
112.69
Cash Conversion Cycle
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
Total Debt/Equity
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
0.54
Interest Cover
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13
1.84

News Update:


  • Strides Pharma Science’s arm gets USFDA’s nod for Generic Suprep Bowel Prep Kit
    23rd Nov 2023, 09:24 AM

    The Product has a market size of $143 Million per IQVIA. The Product will be manufactured at the company’s facility in Bengaluru

    Read More
  • Strides Pharma Science’s arm gets USFDA’s nod for Levetiracetam Oral Solution
    21st Nov 2023, 11:29 AM

    The product will be manufactured at the company’s facility in Bengaluru

    Read More
  • Strides Pharma Scien - Quarterly Results
    30th Oct 2023, 12:16 PM

    Read More
  • Strides Pharma’s arm to sell manufacturing facility for $15 million
    30th Oct 2023, 11:30 AM

    Proceeds from the transaction will be utilized for debt reduction

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for EET tablets
    4th Oct 2023, 17:20 PM

    The product will be manufactured at the company’s facility in Bengaluru

    Read More
  • Strides Pharma Science to demerge CDMO, soft gelatin biz into separate entity
    26th Sep 2023, 15:59 PM

    It is proposed to combine the identified CDMO business of Strides and the identified CDMO business of Steriscience under Stelis

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Icosapent Ethyl Capsules
    25th Sep 2023, 11:56 AM

    The product will be manufactured at the company’s facility in Bengaluru

    Read More
  • Strides Pharma’s arm gets USFDA’s tentative nod for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets
    15th Sep 2023, 16:00 PM

    The Product will be manufactured at the company’s facility in Bengaluru

    Read More
  • Strides Pharma Science’s arm gets tentative approval for Dolutegravir 50mg tablets
    14th Sep 2023, 18:18 PM

    The company has set a target to launch around 60 new products over three years in the US

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Sevelamer Carbonate for Oral Suspension
    9th Sep 2023, 14:23 PM

    The approval completes the company's Sevelamer Carbonate portfolio

    Read More
  • Strides Pharma Science gets nod to acquire 100% stake in Strides Pharma Services
    7th Sep 2023, 11:14 AM

    The Board of Directors of the company at their meeting held on September 7, 2023, has approved the same

    Read More
  • Strides Pharma Science’s arm gets USFDA’s nod for Mycophenolate Mofetil for Oral Suspension
    30th Aug 2023, 12:12 PM

    The approval bolsters the company's Mycophenolate Mofetil portfolio, which already includes numerous products in which the company is a market leader

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.